- Lucid Diagnostics (LUCD, Financial) partners with Hoag to expand esophageal precancer testing across California.
- The EsoGuard® test offers a quick, non-endoscopic 3-minute DNA test for early detection.
- This collaboration aims to serve as a model for future healthcare system partnerships.
Lucid Diagnostics Inc. (LUCD) has announced a partnership with Hoag, a prominent California healthcare network, to launch a esophageal precancer testing program using the EsoGuard® Esophageal DNA Test. This collaboration aims to increase access to esophageal precancer testing across Hoag's healthcare delivery network, including digestive health, primary care, and concierge medicine programs.
Dr. Kenneth J. Chang, Executive Medical Director at Hoag's Digestive Health Institute, emphasized the significance of this initiative, noting that the incidence of esophageal cancer has surged tenfold over the past four decades. EsoGuard provides a rapid, non-endoscopic test that identifies at-risk patients within three minutes. This test is critical for patients who have been historically difficult to diagnose early in the disease's progression.
Lucid's CEO, Dr. Lishan Aklog, views this partnership as a strategic milestone, highlighting the importance of wide accessibility for the EsoGuard test within major healthcare systems. He believes this model of integration could become a blueprint for future partnerships with other leading health networks. The collaboration seeks to address a pressing healthcare need by facilitating early detection and potentially reducing esophageal cancer rates.
For Lucid Diagnostics, partnering with a healthcare leader such as Hoag not only extends the reach of their EsoGuard test within Orange County but also aligns with their mission of expanding cancer prevention through early detection strategies. This development may potentially increase test volumes and accelerate revenue growth, marking a significant step in Lucid's commercial strategy.
